Hogan Lovells team advises Gilead Sciences in a license agreement with Xencor, Inc. for Use of XmAb® Antibody Technologies in investigational agents for HIV
Press releases
| 14
January
2020
New York, 14 January 2020 – International law firm Hogan Lovells has advised Gilead Sciences, Inc. in entering into a technology license agreement with Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma, and allergic diseases.
The agreement will grand Gilead Sciences access to Xencor’s Xtend™ extended half-life and Cytotoxic XmAb® Fc technologies for developing and commercializing GS-9722, Gilead’s first-in-class effector-enhanced broadly neutralizing anti-HIV antibody, which is currently in Phase 1 clinical development.
The value of the deal was not disclosed. More about the terms of the agreement, can be found here.
The Hogan Lovells team advising Gilead Sciences was led by Corporate partner Adam Golden and senior associate Jeffrey Jay.